Sunshine Biopharma (SBFM) Cash from Financing Activities (2010 - 2025)
Sunshine Biopharma (SBFM) posted Cash from Financing Activities of $724500.0 for Q4 2025, up 859.15% on a QoQ basis from $75536.0 in Q3 2025, and down 55.23% year-over-year from $1.6 million in Q4 2024.
Sunshine Biopharma (SBFM) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Sunshine Biopharma's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $724500.0 for Q4 2025.
- Quarterly Cash from Financing Activities fell 55.23% year-over-year to $724500.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 12.68% YoY) and the FY2025 annual result came in at $4.7 million, down 46.9% from the prior year.
- Cash from Financing Activities was $724500.0 for Q4 2025 at Sunshine Biopharma, up from $75536.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $29.1 million in Q2 2022 and bottomed at -$2.1 million in Q4 2022.
- A 5-year average of $3.1 million and a median of $724500.0 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 8758.42% — and 2025, when it jumped 12670.67%.
- Sunshine Biopharma's Cash from Financing Activities stood at -$23664.0 in 2021, then plunged by 8758.42% to -$2.1 million in 2022, then jumped by 98.54% to -$30519.0 in 2023, then jumped by 5402.28% to $1.6 million in 2024, then plunged by 55.23% to $724500.0 in 2025.
- Business Quant data shows SBFM's Cash from Financing Activities at $724500.0 in Q4 2025, $75536.0 in Q3 2025, and $3.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -1.48 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 724,500.00 |
| Dec 31, 2025 | 724,500.00 |
| Sep 30, 2025 | 75,536.00 |
| Sep 30, 2025 | 75,536.00 |
| Jun 30, 2025 | 3.59 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 355,297.00 |
| Mar 31, 2025 | 355,297.00 |
| Dec 31, 2024 | 1.62 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | -28,583.00 |
| Jun 30, 2024 | -28,583.00 |
| Mar 31, 2024 | 5.40 Mn |
| Mar 31, 2024 | 5.40 Mn |
| Dec 31, 2023 | -30,519.00 |
| Dec 31, 2023 | -30,519.00 |
| Sep 30, 2023 | -63,566.00 |
| Sep 30, 2023 | -63,566.00 |